Document is current

Article History

Received: 19 November 2018

Accepted: 8 May 2019

First Online: 29 May 2019

Ethics approval and consent to participate

: The protocol and consent forms were approved by the Partners Human Research Committee. All procedures followed were in accordance with the ethical standards of the responsible institutional or regional committee on human experimentation or in accordance with the Helsinki Declaration of 1975, as revised in 1983. All participants provided written informed consent.

: <b>N/</b>a

: Anne-Marie Wills M.D., M.P.H. has received research funding from the ALS Association, has participated in clinical trials funded by Acorda, Biogen, Bristol-Myers Squibb, Sanofi/Genzyme, Pfizer and received consultant payments from Acorda, Mitsubishi Tanabe Pharma America, and  Accordant, a CVS/Caremark disease management company.Jamie Garry MS RD, reports grants from ALS Association, grants from NIH/NCRR, during the conduct of the study.Jane Hubbard MS RD reports grants from ALS Association, grants from NIH/NCRR, during the conduct of the study.Taylor Mezoian BS has nothing to disclose.Christopher T. Breen BA has nothing to disclose.Courtney Ortiz- Miller BA has nothing to disclose.Paige Nalipinski MA SLP has nothing to disclose.Stacey Sullivan MS SLP has nothing to disclose.James Berry MD MPH, has been a consultant for MT Pharma, Denali Therapeutics, Anelixis Therapeutics, held a research fellowship position with Voyager Therapeutics, and been a Site Investigator for projects sponsored by Brainstorm Cell Therapeutics, Neuraltus, Cytokinetics, and Amylyx.Merit Cudkowicz MD MSc. Has received grants from the NINDS, and received consulting funds from Lilly, MT Pharma, Orion, Cytokinetics, Biohaven, Waves and ImmunityPharm.Sabrina Paganoni MD PhD, has received research funding from the ALS Association, the American Academy of Neurology, ALS Finding a Cure, the Salah Foundation, and Amylyx.James Chan MA has nothing to disclose.Eric A. Macklin PhD serves on Data and Safety Monitoring Boards for Acorda Therapeutics and Shire Human Genetic Therapies, received research funds and served on a Steering Committee for Acorda Therapeutics, and consulted for Myolex Inc. and Lavin Consulting.Competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.